Zofran MDL Plaintiffs Say ‘Clear Evidence’ Preemption Motion Is Premature

(January 20, 2016, 11:49 AM EST) -- BOSTON — Plaintiffs in the Zofran birth defect multidistrict litigation on Jan. 5 opposed defendant GlaxoSmithKline LLC’s (GSK) motion to dismiss the entire litigation, saying that if there is any “clear evidence” that the Food and Drug Administration rejected a warning about birth defects, that record has not yet been developed (In Re: Zofran [Ondansetron] Products Liability Litigation, MDL Docket No. 2657, No. 15-md-2657, D. Mass.).

(Zofran dismissal opposition available. Document #28-160121-011Z.)

Zofran was approved to treat nausea from chemotherapy or after certain surgery. Plaintiffs allege...
To view the full article, register now.